<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00066573</url>
  </required_header>
  <id_info>
    <org_study_id>MA27</org_study_id>
    <secondary_id>CAN-NCIC-MA27</secondary_id>
    <secondary_id>NCCTG-MA27</secondary_id>
    <secondary_id>CALGB-CAN-NCIC-MA27</secondary_id>
    <secondary_id>ECOG-CAN-NCIC-MA27</secondary_id>
    <secondary_id>SWOG-CAN-NCIC-MA27</secondary_id>
    <secondary_id>IBCSG-30-04</secondary_id>
    <secondary_id>EUDRACT-2005-001893-28</secondary_id>
    <secondary_id>CDR0000316325</secondary_id>
    <nct_id>NCT00066573</nct_id>
    <nct_alias>NCT00438529</nct_alias>
  </id_info>
  <brief_title>Exemestane or Anastrozole in Treating Postmenopausal Women Who Have Undergone Surgery for Primary Breast Cancer</brief_title>
  <official_title>A Randomized Phase III Trial Of Exemestane Versus Anastrozole In Postmenopausal Women With Receptor Positive Primary Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NCIC Clinical Trials Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>North Central Cancer Treatment Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cancer and Leukemia Group B</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eastern Cooperative Oncology Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Southwest Oncology Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>International Breast Cancer Study Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Canadian Cancer Trials Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy, using
      exemestane or anastrozole, may fight breast cancer by reducing the production of estrogen. It
      is not yet known whether exemestane is more effective than anastrozole in preventing the
      recurrence of breast cancer.

      PURPOSE: This randomized phase III trial is studying exemestane to see how well it works
      compared to anastrozole in preventing cancer recurrence in postmenopausal women who have
      undergone surgery for primary breast cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Compare the event-free survival of postmenopausal women with receptor-positive primary
           breast cancer when treated with exemestane vs anastrozole.

      Secondary

        -  Compare the overall survival of patients treated with these regimens.

        -  Compare the time to distant recurrence in patients treated with these regimens.

        -  Compare the incidence of new primary contralateral breast cancer in patients treated
           with these regimens.

        -  Compare the incidence of all clinical fractures, specifically hip and vertebral
           fractures, in patients treated with these regimens.

        -  Compare cardiovascular morbidity and mortality (i.e., significant coronary heart
           disease, which includes myocardial infarctions and angina requiring percutaneous
           transluminal coronary angioplasty or coronary artery bypass graft, fatal and nonfatal
           strokes, and all vascular deaths) in patients treated with these regimens.

        -  Correlate therapy induced changes in breast density with plasma hormones and growth
           factors, drug levels of exemestane and anastrozole, genetic variation and breast cancer
           recurrence or contralateral events in patients treated with these regimens.

        -  Compare the toxic effects of these regimens in these patients.

      OUTLINE: This is a randomized, multicenter study. Patients are stratified according to lymph
      node status at diagnosis (negative vs positive vs unknown), prior adjuvant chemotherapy (yes
      vs no), and herceptin use (yes vs no). Patients are randomized to 1 of 2 treatment arms.

        -  Arm I: Patients receive oral exemestane (25 mg) once daily for 5 years.

        -  Arm II: Patients receive oral anastrozole (1 mg) once daily for 5 years. In both arms,
           treatment continues in the absence of disease progression or unacceptable toxicity.

      Patients are followed every 6 months during the first year of study participation and
      annually thereafter.

      PROJECTED ACCRUAL: A total of 6,840 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2003</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Event-free Survival</measure>
    <time_frame>5 years</time_frame>
    <description>Event free survival, the primary endpoint of this study, is defined as the time from randomization to the time of documented locoregional or distant recurrence, new primary breast cancer, or death from any cause.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival: Percentage of Participants Alive at 5 Years</measure>
    <time_frame>5 years</time_frame>
    <description>Overall survival is defined as the time from randomization to the time of death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distant Disease-free Survival: Number of Participants Without Documented Distant Recurrence</measure>
    <time_frame>5 years</time_frame>
    <description>Time to distant disease-free survival (DDFS) is defined as the time from randomization to the time of documented distant recurrence. Distant recurrence is the cancer coming back in a part of the body away from the breast, such as the bones or liver.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Fracture Rate: Number of Participants With Bone Fractures.</measure>
    <time_frame>8 years</time_frame>
    <description>Clinical fracture at any time, including hip, spine, wrist fractures and other bone fractures.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">7576</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Exemestane</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral exemestane (25 mg) once daily for 5 years.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Anastrozole</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive oral anastrozole (1 mg) once daily for 5 years.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>anastrozole</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Anastrozole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>exemestane</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Exemestane</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed invasive breast cancer

               -  pT1-3; pNX, pN0-2 or pN3*; M0

               -  Neoadjuvant patients are eligible no earlier than 3 weeks or later than 3 months
                  after excisional surgery, provided both the clinical-diagnostic staging of cancer
                  and postsurgical resection-pathologic staging of cancer meet the requirements for
                  primary tumor, regional lymph nodes, and distant metastasis classification NOTE:
                  *Only when the sole basis for this classification is the presence of 10 or more
                  involved axillary lymph nodes

          -  Completely resected disease

               -  Primary surgery performed at least 3 weeks but no more than 3 months before study
                  entry (if no chemotherapy was given)

                    -  Primary surgery is defined as the last surgery at which histologic evidence
                       of invasive or in situ disease was present in the pathology specimen

               -  Patients with positive sentinel lymph node biopsy are eligible provided they have
                  had a subsequent axillary lymph node dissection

          -  No metachronous breast cancer

          -  Bilateral mammogram within the past 12 months unless initial surgery was a total
             mastectomy, in which case only a mammogram of the remaining breast is required

          -  No metastases confirmed by 1 of the following methods:

               -  Bone scan* (required only if alkaline phosphatase is at least 2 times normal
                  and/or there are symptoms of metastatic disease)

               -  Abdominal ultrasound or CT scan (required only if AST/ALT or alkaline phosphatase
                  is at least 2 times normal, unless the elevation is in the bone fraction)

               -  Chest x-ray NOTE: *Confirmatory x-ray, CT scan, or MRI required if the bone scan
                  results are questionable

          -  No locally recurrent disease

          -  No prior or concurrent carcinoma in situ of the contralateral breast treated with
             partial mastectomy and/or hormonal therapy

               -  Patients with prior or concurrent carcinoma in situ of the ipsilateral breast are
                  eligible provided the tumor was completely excised AND they have not received
                  prior hormonal therapy

          -  Hormone receptor status:

               -  Estrogen receptor- and/or progesterone receptor-positive by immunohistochemistry
                  or tumor receptor content ≥ 10 fmol/mg protein

        PATIENT CHARACTERISTICS:

        Age

          -  Postmenopausal

        Sex

          -  Female

        Menopausal status

          -  Postmenopausal prior to chemotherapy, defined as 1 of the following:

               -  Over 60 years of age

               -  Age 45-59 with spontaneous cessation of menses for more than 1 year prior to
                  study entry

               -  Age 45-59 with menses ceasing (secondary to hysterectomy or spontaneously) within
                  the past year AND a follicle-stimulating hormone (FSH) level prior to study entry
                  in the postmenopausal range*

               -  Age 45-59, previously on hormone replacement therapy (HRT) and have discontinued
                  HRT upon diagnosis of this malignancy AND has an FSH level prior to study entry
                  in the postmenopausal range*

               -  Has undergone bilateral oophorectomy NOTE: *By institutional standards OR &gt; 34.4
                  IU/L if institutional range is not available)

        Performance status

          -  ECOG 0-2

        Life expectancy

          -  At least 5 years

        Hematopoietic

          -  WBC at least 3,000/mm^3 OR

          -  Granulocyte count at least 1,500/mm^3 AND

          -  Platelet count at least 100,000/mm^3

        Hepatic

          -  See Disease Characteristics

          -  AST and/or ALT less than 2 times upper limit of normal (ULN)*

          -  Alkaline phosphatase less than 2 times ULN* NOTE: *Unless imaging examinations have
             ruled out metastatic disease

        Renal

          -  Not specified

        Other

          -  Able to swallow study medication and have adequate unassisted oral intake in order to
             maintain reasonable nutrition status

          -  No other non-breast malignancy within the past 5 years except adequately treated
             nonmelanoma skin cancer, curatively treated carcinoma in situ of the cervix, or other
             curatively treated solid tumors with no evidence of disease for at least 5 years

          -  No other concurrent medical or psychiatric condition that would preclude study
             participation and/or interfere with results

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  Prior and concurrent trastuzumab (Herceptin®) allowed

        Chemotherapy

          -  See Disease Characteristics

          -  At least 3 weeks but no more than 3 months since prior chemotherapy

          -  Prior adjuvant chemotherapy allowed

        Endocrine therapy

          -  See Disease Characteristics

          -  No prior aromatase inhibitor

          -  No prior tamoxifen or other selective estrogen receptor modulators (SERMs) except
             raloxifene

               -  At least 3 weeks since prior raloxifene

          -  At least 3 weeks since prior and no concurrent over-the-counter products or
             supplements considered to have an estrogenic effect, including any of the following:

               -  Ginseng

               -  Ginkgo biloba

               -  Black cohosh

               -  Dong quai

               -  Fortified soy supplements (e.g., phytoestrogen preparations)

          -  At least 3 weeks since other prior hormonal therapy or steroids considered to have an
             estrogenic effect

          -  No concurrent estrogens, progesterones, androgens, or SERMs

               -  Concurrent intermittent vaginal estrogens (e.g., vagifem, estrogen vaginal cream,
                  testosterone, estradiol vaginal gel, or Estring) allowed if other local measures
                  for intractable vaginal atrophy are insufficient

          -  No other concurrent therapy that would have an estrogenic effect, including endocrine
             therapy, hormonal therapy, or steroid therapy

        Radiotherapy

          -  See Disease Characteristics

          -  Prior adjuvant radiotherapy allowed

          -  Concurrent radiotherapy allowed

        Surgery

          -  See Disease Characteristics
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul E. Goss, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>James N. Ingle, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Matthew J. Ellis, MD, PhD, FRCP</last_name>
    <role>Study Chair</role>
    <affiliation>Washington University Siteman Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>George W. Sledge, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Indiana University Melvin and Bren Simon Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>George T. Budd, MD</last_name>
    <role>Study Chair</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Manuela Rabaglio, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Inselspital, Berne</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tom Baker Cancer Centre</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lethbridge Cancer Centre</name>
      <address>
        <city>Lethbridge</city>
        <state>Alberta</state>
        <zip>T1J 1W5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BCCA - Cancer Centre for the Southern Interior</name>
      <address>
        <city>Kelowna</city>
        <state>British Columbia</state>
        <zip>V1Y 5L3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penticton Regional Hospital</name>
      <address>
        <city>Penticton</city>
        <state>British Columbia</state>
        <zip>V2A 3G6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BCCA - Fraser Valley Cancer Centre</name>
      <address>
        <city>Surrey</city>
        <state>British Columbia</state>
        <zip>V3V 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BCCA - Vancouver Cancer Centre</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BCCA - Vancouver Island Cancer Centre</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <zip>V8R 6V5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CancerCare Manitoba</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3E 0V9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Moncton Hospital</name>
      <address>
        <city>Moncton</city>
        <state>New Brunswick</state>
        <zip>E1C 6Z8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Vitalite Health Network - Dr. Leon Richard</name>
      <address>
        <city>Moncton</city>
        <state>New Brunswick</state>
        <zip>E1C 8X3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlantic Health Sciences Corporation</name>
      <address>
        <city>Saint John</city>
        <state>New Brunswick</state>
        <zip>E2L 4L2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. H. Bliss Murphy Cancer Centre</name>
      <address>
        <city>St. John's</city>
        <state>Newfoundland and Labrador</state>
        <zip>AIB 3V6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Quinte Healthcare Corporation</name>
      <address>
        <city>Belleville</city>
        <state>Ontario</state>
        <zip>K8N 5A9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cambridge Memorial Hospital</name>
      <address>
        <city>Cambridge</city>
        <state>Ontario</state>
        <zip>N1R 3G2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Juravinski Cancer Centre at Hamilton Health Sciences</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 5C2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Centre of Southeastern Ontario at Kingston</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7L 5P9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grand River Regional Cancer Centre</name>
      <address>
        <city>Kitchener</city>
        <state>Ontario</state>
        <zip>N2G 1G3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>London Regional Cancer Program</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Credit Valley Hospital</name>
      <address>
        <city>Mississauga</city>
        <state>Ontario</state>
        <zip>L5M 2N1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stronach Regional Health Centre at Southlake</name>
      <address>
        <city>Newmarket</city>
        <state>Ontario</state>
        <zip>L3Y 2P9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lakeridge Health Oshawa</name>
      <address>
        <city>Oshawa</city>
        <state>Ontario</state>
        <zip>L1G 2B9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Algoma District Cancer Program</name>
      <address>
        <city>Sault Ste. Marie</city>
        <state>Ontario</state>
        <zip>P6B 0A8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Niagara Health System</name>
      <address>
        <city>St. Catharines</city>
        <state>Ontario</state>
        <zip>L2R 7C6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Cancer Program of the Hopital Regional</name>
      <address>
        <city>Sudbury</city>
        <state>Ontario</state>
        <zip>P3E 5J1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thunder Bay Regional Health Science Centre</name>
      <address>
        <city>Thunder Bay</city>
        <state>Ontario</state>
        <zip>P7B 6V4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Odette Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Michael's Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B 1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. Health Network-Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Trillium Health Centre - West Toronto</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M9C 1A5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Windsor Regional Cancer Centre</name>
      <address>
        <city>Windsor</city>
        <state>Ontario</state>
        <zip>N8W 2X3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PEI Cancer Treatment Centre,Queen Elizabeth Hospital</name>
      <address>
        <city>Charlottetown</city>
        <state>Prince Edward Island</state>
        <zip>C1A 8T5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre de Sante et de services sociaux de Gatineau</name>
      <address>
        <city>Gatineau</city>
        <state>Quebec</state>
        <zip>J8P 7H2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Charles LeMoyne</name>
      <address>
        <city>Greenfield Park</city>
        <state>Quebec</state>
        <zip>J4V 2H1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHUM - Hopital Notre-Dame</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2L 4M1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHA-Hopital Du St-Sacrement</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <zip>G1S 4L8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier universitaire de Sherbrooke</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allan Blair Cancer Centre</name>
      <address>
        <city>Regina</city>
        <state>Saskatchewan</state>
        <zip>S4T 7T1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saskatoon Cancer Centre</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7N 4H4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <removed_countries>
    <country>Australia</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Puerto Rico</country>
    <country>South Africa</country>
    <country>Switzerland</country>
    <country>United States</country>
  </removed_countries>
  <results_reference>
    <citation>Moy B, Elliott CR, Chapman J-AW, et al.: NCIC CTG MA.27: menopausal symptoms of ethnic minority women. [Abstract] Breast Cancer Res Treat 100 (Suppl 1): A-3059, S144, 2006.</citation>
  </results_reference>
  <results_reference>
    <citation>Goss PE, Ingle JN, Pritchard KI, Ellis MJ, Sledge GW, Budd GT, Rabaglio M, Ansari RH, Johnson DB, Tozer R, D'Souza DP, Chalchal H, Spadafora S, Stearns V, Perez EA, Liedke PE, Lang I, Elliott C, Gelmon KA, Chapman JA, Shepherd LE. Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27--a randomized controlled phase III trial. J Clin Oncol. 2013 Apr 10;31(11):1398-404. doi: 10.1200/JCO.2012.44.7805. Epub 2013 Jan 28.</citation>
    <PMID>23358971</PMID>
  </results_reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 6, 2003</study_first_submitted>
  <study_first_submitted_qc>August 6, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 7, 2003</study_first_posted>
  <results_first_submitted>April 16, 2014</results_first_submitted>
  <results_first_submitted_qc>April 16, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 15, 2014</results_first_posted>
  <last_update_submitted>March 21, 2018</last_update_submitted>
  <last_update_submitted_qc>March 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage IIIA breast cancer</keyword>
  <keyword>stage I breast cancer</keyword>
  <keyword>stage II breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Exemestane</mesh_term>
    <mesh_term>Anastrozole</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Exemestane</title>
          <description>Patients receive oral exemestane (25 mg) once daily for 5 years.
exemestane: Given orally</description>
        </group>
        <group group_id="P2">
          <title>Anastrozole</title>
          <description>Patients receive oral anastrozole (1 mg) once daily for 5 years.
anastrozole: Given orally</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3789"/>
                <participants group_id="P2" count="3787"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3761"/>
                <participants group_id="P2" count="3759"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Did not received protocol treatment</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Exemestane</title>
          <description>Patients receive oral exemestane (25 mg) once daily for 5 years.
exemestane: Given orally</description>
        </group>
        <group group_id="B2">
          <title>Anastrozole</title>
          <description>Patients receive oral anastrozole (1 mg) once daily for 5 years.
anastrozole: Given orally</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3789"/>
            <count group_id="B2" value="3787"/>
            <count group_id="B3" value="7576"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.9" lower_limit="35.9" upper_limit="93.6"/>
                    <measurement group_id="B2" value="64.3" lower_limit="32.3" upper_limit="95.1"/>
                    <measurement group_id="B3" value="64.1" lower_limit="32.3" upper_limit="95.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3789"/>
                    <measurement group_id="B2" value="3787"/>
                    <measurement group_id="B3" value="7576"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Event-free Survival</title>
        <description>Event free survival, the primary endpoint of this study, is defined as the time from randomization to the time of documented locoregional or distant recurrence, new primary breast cancer, or death from any cause.</description>
        <time_frame>5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Exemestane</title>
            <description>Patients receive oral exemestane (25 mg) once daily for 5 years.
exemestane: Given orally</description>
          </group>
          <group group_id="O2">
            <title>Anastrozole</title>
            <description>Patients receive oral anastrozole (1 mg) once daily for 5 years.
anastrozole: Given orally</description>
          </group>
        </group_list>
        <measure>
          <title>Event-free Survival</title>
          <description>Event free survival, the primary endpoint of this study, is defined as the time from randomization to the time of documented locoregional or distant recurrence, new primary breast cancer, or death from any cause.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3789"/>
                <count group_id="O2" value="3787"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88" lower_limit="87" upper_limit="89"/>
                    <measurement group_id="O2" value="89" lower_limit="88" upper_limit="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>To detect a hazard ratio (HR) of 0.80 between exemestane and anastrozole (ie, an improvement in 5-year EFS from 87.5% to 89.9%, with a two-sided 5% level test and 80% power, 6,840 patients and 630 events were needed for final analysis.</non_inferiority_desc>
            <p_value>0.85</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.87</ci_lower_limit>
            <ci_upper_limit>1.18</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival: Percentage of Participants Alive at 5 Years</title>
        <description>Overall survival is defined as the time from randomization to the time of death from any cause.</description>
        <time_frame>5 years</time_frame>
        <population>Intend to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Exemestane</title>
            <description>Patients receive oral exemestane (25 mg) once daily for 5 years.
exemestane: Given orally</description>
          </group>
          <group group_id="O2">
            <title>Anastrozole</title>
            <description>Patients receive oral anastrozole (1 mg) once daily for 5 years.
anastrozole: Given orally</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival: Percentage of Participants Alive at 5 Years</title>
          <description>Overall survival is defined as the time from randomization to the time of death from any cause.</description>
          <population>Intend to treat</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3789"/>
                <count group_id="O2" value="3787"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92" lower_limit="91" upper_limit="93"/>
                    <measurement group_id="O2" value="92" lower_limit="91" upper_limit="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>No power calculation for secondary analysis</non_inferiority_desc>
            <p_value>0.46</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.93</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.77</ci_lower_limit>
            <ci_upper_limit>1.13</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Distant Disease-free Survival: Number of Participants Without Documented Distant Recurrence</title>
        <description>Time to distant disease-free survival (DDFS) is defined as the time from randomization to the time of documented distant recurrence. Distant recurrence is the cancer coming back in a part of the body away from the breast, such as the bones or liver.</description>
        <time_frame>5 years</time_frame>
        <population>Intent to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Exemestane</title>
            <description>Patients receive oral exemestane (25 mg) once daily for 5 years.
exemestane: Given orally</description>
          </group>
          <group group_id="O2">
            <title>Anastrozole</title>
            <description>Patients receive oral anastrozole (1 mg) once daily for 5 years.
anastrozole: Given orally</description>
          </group>
        </group_list>
        <measure>
          <title>Distant Disease-free Survival: Number of Participants Without Documented Distant Recurrence</title>
          <description>Time to distant disease-free survival (DDFS) is defined as the time from randomization to the time of documented distant recurrence. Distant recurrence is the cancer coming back in a part of the body away from the breast, such as the bones or liver.</description>
          <population>Intent to treat</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3789"/>
                <count group_id="O2" value="3787"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="157"/>
                    <measurement group_id="O2" value="164"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Fracture Rate: Number of Participants With Bone Fractures.</title>
        <description>Clinical fracture at any time, including hip, spine, wrist fractures and other bone fractures.</description>
        <time_frame>8 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Exemestane</title>
            <description>Patients receive oral exemestane (25 mg) once daily for 5 years.
exemestane: Given orally</description>
          </group>
          <group group_id="O2">
            <title>Anastrozole</title>
            <description>Patients receive oral anastrozole (1 mg) once daily for 5 years.
anastrozole: Given orally</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Fracture Rate: Number of Participants With Bone Fractures.</title>
          <description>Clinical fracture at any time, including hip, spine, wrist fractures and other bone fractures.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3789"/>
                <count group_id="O2" value="3787"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="358"/>
                    <measurement group_id="O2" value="354"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>8 years</time_frame>
      <desc>Participants at Risk of Adverse Event or SAE were those who received at least one dose of protocol therapy.</desc>
      <group_list>
        <group group_id="E1">
          <title>Exemestane</title>
          <description>Patients receive oral exemestane (25 mg) once daily for 5 years.
exemestane: Given orally</description>
        </group>
        <group group_id="E2">
          <title>Anastrozole</title>
          <description>Patients receive oral anastrozole (1 mg) once daily for 5 years.
anastrozole: Given orally</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="3761"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="3759"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac ischemia/infarction</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3759"/>
              </event>
              <event>
                <sub_title>Left ventricular systolic dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3759"/>
              </event>
              <event>
                <sub_title>Restrictive cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3759"/>
              </event>
              <event>
                <sub_title>Supraven.arrhyth. Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3759"/>
              </event>
              <event>
                <sub_title>Ventric.arrhyth. Trigeminy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3759"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3761"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3759"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blurred vision</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3759"/>
              </event>
              <event>
                <sub_title>Nyctalopia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3761"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3759"/>
              </event>
              <event>
                <sub_title>Ocular - Other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3759"/>
              </event>
              <event>
                <sub_title>Retinopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3759"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3759"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3759"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Bilirubin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3759"/>
              </event>
              <event>
                <sub_title>Creatinine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3759"/>
              </event>
              <event>
                <sub_title>cTnI</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3759"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3759"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>CNS ischemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3761"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3759"/>
              </event>
              <event>
                <sub_title>Neurology - Other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3759"/>
              </event>
              <event>
                <sub_title>Neuropathy-motor</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3761"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3759"/>
              </event>
              <event>
                <sub_title>Neuropathy: cranial CN VIII</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3759"/>
              </event>
              <event>
                <sub_title>Speech impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3761"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3759"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3761"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3759"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3759"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Incontinence, urinary</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3761"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3759"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3761"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3759"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombosis/thrombus/embolism</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3761"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3759"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3556" subjects_at_risk="3761"/>
                <counts group_id="E2" subjects_affected="3543" subjects_at_risk="3759"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="614" subjects_at_risk="3761"/>
                <counts group_id="E2" subjects_affected="606" subjects_at_risk="3759"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="464" subjects_at_risk="3761"/>
                <counts group_id="E2" subjects_affected="414" subjects_at_risk="3759"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="399" subjects_at_risk="3761"/>
                <counts group_id="E2" subjects_affected="363" subjects_at_risk="3759"/>
              </event>
              <event>
                <sub_title>Heartburn</sub_title>
                <counts group_id="E1" subjects_affected="574" subjects_at_risk="3761"/>
                <counts group_id="E2" subjects_affected="556" subjects_at_risk="3759"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="436" subjects_at_risk="3761"/>
                <counts group_id="E2" subjects_affected="442" subjects_at_risk="3759"/>
              </event>
              <event>
                <sub_title>Pain Abdomen NOS</sub_title>
                <counts group_id="E1" subjects_affected="202" subjects_at_risk="3761"/>
                <counts group_id="E2" subjects_affected="220" subjects_at_risk="3759"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Edema: limb</sub_title>
                <counts group_id="E1" subjects_affected="749" subjects_at_risk="3761"/>
                <counts group_id="E2" subjects_affected="760" subjects_at_risk="3759"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1697" subjects_at_risk="3761"/>
                <counts group_id="E2" subjects_affected="1749" subjects_at_risk="3759"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" subjects_affected="290" subjects_at_risk="3761"/>
                <counts group_id="E2" subjects_affected="292" subjects_at_risk="3759"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Cholesterol</sub_title>
                <counts group_id="E1" subjects_affected="591" subjects_at_risk="3761"/>
                <counts group_id="E2" subjects_affected="677" subjects_at_risk="3759"/>
              </event>
              <event>
                <sub_title>Weight gain</sub_title>
                <counts group_id="E1" subjects_affected="257" subjects_at_risk="3761"/>
                <counts group_id="E2" subjects_affected="286" subjects_at_risk="3759"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" subjects_affected="229" subjects_at_risk="3761"/>
                <counts group_id="E2" subjects_affected="218" subjects_at_risk="3759"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="238" subjects_at_risk="3761"/>
                <counts group_id="E2" subjects_affected="249" subjects_at_risk="3759"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="347" subjects_at_risk="3761"/>
                <counts group_id="E2" subjects_affected="373" subjects_at_risk="3759"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="264" subjects_at_risk="3761"/>
                <counts group_id="E2" subjects_affected="242" subjects_at_risk="3759"/>
              </event>
              <event>
                <sub_title>Osteoporosis</sub_title>
                <counts group_id="E1" subjects_affected="1243" subjects_at_risk="3761"/>
                <counts group_id="E2" subjects_affected="1369" subjects_at_risk="3759"/>
              </event>
              <event>
                <sub_title>Pain Back</sub_title>
                <counts group_id="E1" subjects_affected="480" subjects_at_risk="3761"/>
                <counts group_id="E2" subjects_affected="504" subjects_at_risk="3759"/>
              </event>
              <event>
                <sub_title>Pain Bone</sub_title>
                <counts group_id="E1" subjects_affected="381" subjects_at_risk="3761"/>
                <counts group_id="E2" subjects_affected="410" subjects_at_risk="3759"/>
              </event>
              <event>
                <sub_title>Pain Extremity-limb</sub_title>
                <counts group_id="E1" subjects_affected="468" subjects_at_risk="3761"/>
                <counts group_id="E2" subjects_affected="511" subjects_at_risk="3759"/>
              </event>
              <event>
                <sub_title>Pain Joint</sub_title>
                <counts group_id="E1" subjects_affected="2085" subjects_at_risk="3761"/>
                <counts group_id="E2" subjects_affected="2086" subjects_at_risk="3759"/>
              </event>
              <event>
                <sub_title>Pain Muscle</sub_title>
                <counts group_id="E1" subjects_affected="667" subjects_at_risk="3761"/>
                <counts group_id="E2" subjects_affected="629" subjects_at_risk="3759"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="526" subjects_at_risk="3761"/>
                <counts group_id="E2" subjects_affected="504" subjects_at_risk="3759"/>
              </event>
              <event>
                <sub_title>Neuropathy-sensory</sub_title>
                <counts group_id="E1" subjects_affected="576" subjects_at_risk="3761"/>
                <counts group_id="E2" subjects_affected="528" subjects_at_risk="3759"/>
              </event>
              <event>
                <sub_title>Pain Head/headache</sub_title>
                <counts group_id="E1" subjects_affected="414" subjects_at_risk="3761"/>
                <counts group_id="E2" subjects_affected="399" subjects_at_risk="3759"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="574" subjects_at_risk="3761"/>
                <counts group_id="E2" subjects_affected="521" subjects_at_risk="3759"/>
              </event>
              <event>
                <sub_title>Mood alteration Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="258" subjects_at_risk="3761"/>
                <counts group_id="E2" subjects_affected="229" subjects_at_risk="3759"/>
              </event>
              <event>
                <sub_title>Mood alteration Depression</sub_title>
                <counts group_id="E1" subjects_affected="374" subjects_at_risk="3761"/>
                <counts group_id="E2" subjects_affected="377" subjects_at_risk="3759"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Pain Breast</sub_title>
                <counts group_id="E1" subjects_affected="288" subjects_at_risk="3761"/>
                <counts group_id="E2" subjects_affected="312" subjects_at_risk="3759"/>
              </event>
              <event>
                <sub_title>Vaginal dryness</sub_title>
                <counts group_id="E1" subjects_affected="248" subjects_at_risk="3761"/>
                <counts group_id="E2" subjects_affected="260" subjects_at_risk="3759"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="671" subjects_at_risk="3761"/>
                <counts group_id="E2" subjects_affected="666" subjects_at_risk="3759"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="656" subjects_at_risk="3761"/>
                <counts group_id="E2" subjects_affected="652" subjects_at_risk="3759"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="235" subjects_at_risk="3761"/>
                <counts group_id="E2" subjects_affected="212" subjects_at_risk="3759"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="474" subjects_at_risk="3761"/>
                <counts group_id="E2" subjects_affected="437" subjects_at_risk="3759"/>
              </event>
              <event>
                <sub_title>Sweating</sub_title>
                <counts group_id="E1" subjects_affected="626" subjects_at_risk="3761"/>
                <counts group_id="E2" subjects_affected="603" subjects_at_risk="3759"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flashes</sub_title>
                <counts group_id="E1" subjects_affected="2086" subjects_at_risk="3761"/>
                <counts group_id="E2" subjects_affected="2138" subjects_at_risk="3759"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="300" subjects_at_risk="3761"/>
                <counts group_id="E2" subjects_affected="326" subjects_at_risk="3759"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Wendy Parulekar</name_or_title>
      <organization>NCIC Clinical Trials Group</organization>
      <phone>1-613-533-6430</phone>
      <email>wparulekar@ctg.queensu.ca</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

